|
|
|
| home > white papers > Data Technology as a Catalyst for Growth in the Life Sciences - Aigenpulse |
|
|
 WHITE PAPERS |
|
Aigenpulse
|
|
Data Technology as a Catalyst for Growth in the Life Sciences
|
|
The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline
Sanofi announced today an equity investment of $180 million and a new
strategic collaboration with Owkin comprised of discovery and
development programmes in four exclusive types of cancer, with a total
payment of $90 million for three years plus additional research
milestone-based payments.
More info >> |
|
 |
White Papers |
 |
|
Six Strategies to Stretch Your Limited Drug Supply for Clinical Studies
PCI Pharma Services
Bringing a new drug to market can be a heavy financial burden on any pharmaceutical company. It has become even more burdensome over the last several years as the industry pushes the boundaries of innovation. This is because newer, often more-complex therapies not only increase risk in drug development but also drive costs even higher. A recent analysis of the investment needed to develop a new prescription medicine shows the total cost can be as high as $2.6 billion (1). That number becomes even more staggering when you consider the fact that only about 12 percent of drug candidates that make it to Phase I testing are eventually approved by the FDA (2). The investment companies lose as a result may be too devastating to their bottom line to ever recover.
More info >> |
|
|
|
